June 15 (Reuters) - Invex Therapeutics Ltd (IXC) :
- INVEX RECEIVES WRITTEN RESPONSE FROM FDA ON TYPE C MEETING ON PHASE III CLINICAL TRIAL DESIGN FOR PRESENDIN (EXENATIDE)
- FDA RECOMMENDED INVEX CONSIDER A CLINICALLY MEANINGFUL EFFECT ON VISUAL FUNCTION
- INTENDS TO MEET WITH REGULATORY AND CLINICAL ADVISORS IN COMING WEEKS TO BETTER UNDERSTAND RESPONSE FROM FDA
News: IXC Invex Therapeutics Receives Written Response From FDA On Type C Meeting
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.891M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 12.0¢ | 10.5¢ | $5.901K | 53.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7193 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 21500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/09/2025 (20 minute delay) ? |
| IXC (ASX) Chart |